Oxolamine (citrate)

Oxolamine citrate (SKF-9976 citrate) is an orally active antitussive. Oxolamine citrate can inhibit CYP2B1/2. Oxolamine citrate has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine citrate increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine citrate can be used in respiratory disease research[1][2][3][4].

Product Specifications

CAS Number

[1949-20-8]

Product Name Alternative

SKF-9976 citrate; AF-438 citrate

UNSPSC

12352005

Hazard Statement

H302

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Oxolamine-citrate.html

Purity

99.87

Solubility

DMSO : ≥ 100 mg/mL|H2O : 14.29 mg/mL (ultrasonic)

Smiles

CCN(CC)CCC1=NC(C2=CC=CC=C2)=NO1.O=C(CC(C(O)=O)(O)CC(O)=O)O

Molecular Formula

C20H27N3O8

Molecular Weight

437.44

Precautions

H302

References & Citations

[1]Kirilmaz L, et, al. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. Apr-Jun 1992;9 (2) :167-72.|[2]GIUDICI G, et, al. [On the anti-inflammatory action of oxolamine citrate]. Minerva Med. 1961 Oct 31;52:3752-5.|[3]Zhu X, et al. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28 (3) :125-33. |[4]Dahlgren S, et al. The effect of oxolamine citrate on experimentally produced inflammation in the respiratory organs. Acta Pharmacol Toxicol (Copenh) . 1966;24 (2) :286-96.